IMEIK(300896)2024-04-24 11:37Financial Performance - Revenue for Q1 2024 reached RMB 808.09 million, a 28.24% increase year-over-year[3] - Net profit attributable to shareholders was RMB 527.44 million, up 27.38% compared to the same period last year[3] - Total revenue for the first quarter of 2024 reached 808,088,120.34 yuan, a 28.2% increase compared to the same period last year (630,121,089.65 yuan)[17] - Net profit attributable to the parent company's owners increased to 3,488,349,045.67 yuan, up 17.8% from 2,960,911,557.61 yuan in the previous period[16] - Net profit attributable to parent company owners increased to 527.44 million yuan from 414.07 million yuan in the previous period[18] - Basic earnings per share rose to 2.45 yuan from 1.91 yuan[19] Cash Flow and Liquidity - Operating cash flow increased by 25.73% to RMB 536.87 million, driven by higher sales and improved collections[6] - Investment cash flow turned positive at RMB 430.74 million, a 160.96% increase, mainly due to the redemption of financial products[6] - Operating cash flow increased to 536.87 million yuan from 427.01 million yuan[20] - Investment cash flow turned positive at 430.74 million yuan compared to a negative 706.59 million yuan in the previous period[21] - Cash and cash equivalents at the end of the period reached 3.4 billion yuan, up from 2.9 billion yuan[21] - Cash and cash equivalents increased by 39.6% to 3,396,563,023.47 yuan compared to the beginning of the period (2,433,849,444.16 yuan)[14] Assets and Liabilities - Total assets grew by 6.59% to RMB 7.30 billion as of March 31, 2024[3] - Total assets grew to 7,304,245,958.16 yuan, a 6.6% increase from 6,852,360,636.01 yuan at the beginning of the period[15] - Total liabilities decreased by 22.5% to 284,665,967.31 yuan from 367,321,812.58 yuan at the beginning of the period[15] - Accounts receivable decreased by 26.5% to 151,356,941.40 yuan from 206,068,105.21 yuan at the beginning of the period[14] - Inventory decreased by 9.2% to 45,193,657.63 yuan from 49,771,209.00 yuan at the beginning of the period[14] R&D and Operating Costs - R&D expenses rose by 32.17% to RMB 57.59 million due to increased project activities[6] - R&D expenses rose to 57,591,624.41 yuan, a 32.2% increase from 43,573,802.19 yuan in the same period last year[17] - Operating costs increased by 9.3% to 192,633,344.11 yuan compared to 176,301,626.10 yuan in the same period last year[17] Shareholder and Equity Information - The total number of ordinary shareholders at the end of the reporting period is 53,651[9] - Jian Jun holds the largest share of 31.05%, with 67,187,443 shares[9] - Xiamen Zhixin Junxing Investment Partnership holds 6.41% of the shares, totaling 13,877,244 shares[9] - Shi Yifeng and Xiamen Danrui Investment Partnership each hold 4.85% of the shares, with 10,485,029 shares each[9] - Xiamen Keshang Investment Partnership holds 4.28% of the shares, totaling 9,251,496 shares[9] - The total number of restricted shares at the end of the period is 67,123,843, with no changes during the period[13] - The restricted shares are primarily held by directors, supervisors, and senior management, with 25% of the shares being unlocked each year after their term ends[12] - The top 10 shareholders include both domestic and foreign individuals and entities, with significant holdings in both restricted and unrestricted shares[9] Investment and Fair Value Changes - Investment income rose to 9,973,759.07 yuan, a 43.5% increase from 6,952,756.30 yuan in the same period last year[17] - Fair value changes on investments resulted in a loss of RMB 9.71 million, a 143.77% decline compared to the previous year[6] - Investment income received increased to 7.60 million yuan from 6.72 million yuan[20] Management and Administrative Expenses - Management expenses decreased by 34.57% to RMB 32.92 million, as last year's expenses included significant costs related to the Hong Kong IPO[6] Construction and Capital Expenditure - Construction in progress surged by 140.03% to RMB 35.32 million, reflecting increased investment in the Beautiful Health Industrial Innovation Project[6] ETF and Securities Lending - China Bank Co., Ltd. - Huabao CSI Medical ETF holds 1.42% of the shares, with 3,067,068 shares at the beginning of the period and 2,666,764 shares at the end[11] - The ETF has 544,500 shares lent out through the securities lending business, accounting for 0.25% of the total shares[11] Sales and Payments - Sales revenue from goods and services increased to 896.79 million yuan from 654.48 million yuan[20] - Payments for goods and services rose to 34.02 million yuan from 18.60 million yuan[20] - Employee compensation and benefits increased to 159.75 million yuan from 111.90 million yuan[20] - Tax payments grew to 145.85 million yuan from 86.30 million yuan[20]